The 9th International Cancer Cluster Showcase has been launched on June 8th as a virtual event presenting 20 early-stage oncology companies.
For the first time, the annual International Cancer Cluster Showcase (ICCS) is presented in a digital format. Although we are missing the lively networking elements this year, there is a clear advantage: participants from around the globe can view the full program or selected presentations whenever suitable until July 8th – independent of time-zones and location. The record-high participation with about 400 registrations confirms that this flexible format offers an interesting opportunity to meet new companies in times when travelling is limited.
The organising partners from North America and Europe have jointly selected 20 emerging oncology companies from 8 countries advancing novel therapeutic, diagnostic and digital solutions. The CEOs of this outstanding group of early-stage companies present their latest innovations and partnering opportunities in four thematic sessions.
“We hope that this 9th International Cancer Cluster Showcase again creates novel collaboration opportunities and contacts for presenters and participants and stimulates relevant discussions.”
Jutta Heix, Head of International Affairs, Oslo Cancer Cluster.
A joint welcome from the organising partners opens the first session with the theme Targeting novel mechanisms. Our member EXACT Therapeutics is one of the companies selected for this session. CEO Rafiq Hasan introduces the company’s unique Acoustic Cluster Therapy for ultrasound-mediated, targeted therapeutic enhancement.
“It was important for EXACT Therapeutics to participate at ICCS as this is one of the leading opportunities for us to communicate progress with our innovative Acoustic Cluster Therapy (ACT) platform in oncology to key stakeholders and potential partners.
“We are impressed by the virtual format and the agility with which the in-person meeting was transformed to a digital platform. This ensures that the objectives of the meetings are achieved despite the challenges of the current situation.”
Rafiq Hasan, CEO, EXACT Therapeutics
- Read the press release “Exact Therapeutics appoints new CEO” to learn more
The theme of the second session is Immuno-Oncology and Cell therapy. Here the Oslo Cancer Cluster member Nextera introduces their NextCore technology and relevant applications in oncology.
“It was important for Nextera to present our unique drug and target discovery platform at the stage we are now, since we believe we can enable immuno-oncology therapies to new levels both from efficacy and safety points of view.
“The digital format fosters a great flexibility as well as the message reaches a larger audience.”
Ole Henrik Brekke, Chief Business Officer, Nextera
The third session has the theme Immuno-Oncology, oncolytic viruses and vaccines, featuring companies from the US, UK and France showcasing their technologies and lead candidates.
As final Nordic company, our member Kaiku Health presents their platform for personalized digital health interventions in the fourth session titled Diagnostics and digital health interventions.
“ICCS is a good platform to reach like-minded innovators in oncology interested in making cancer care more personalised. We were happy to have the opportunity to go virtual during these exceptional times.”
Lauri Sippola, CEO and Co-Founder, Kaiku Health
The Virtual International Cancer Cluster Showcase is available online, via the official ICCS website, until 8 July 2020.
Details of all the presenters can be found in the ICCS 2020 event guide.
We kindly thank the sponsors and partners BIO, DNB, Precision for Medicine and Takeda for their ongoing support and program contribution.